Galderma Group N Stock Net Income
| GALD Stock | 154.20 0.40 0.26% |
As of the 22nd of February, Galderma Group retains the Downside Deviation of 1.48, market risk adjusted performance of 0.1403, and Risk Adjusted Performance of 0.0302. Galderma Group technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Galderma Group N variance, jensen alpha, and the relationship between the standard deviation and information ratio to decide if Galderma Group is priced fairly, providing market reflects its last-minute price of 154.2 per share.
Galderma Group Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 10.3193 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 265.6 M | 278.9 M | |
| Net Income Applicable To Common Shares | 265.6 M | 278.9 M | |
| Net Income Per Share | 0.88 | 0.92 | |
| Net Income Per E B T | 0.86 | 0.90 |
Galderma | Net Income |
The evolution of Net Income for Galderma Group N provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Galderma Group compares to historical norms and industry peers.
Latest Galderma Group's Net Income Growth Pattern
Below is the plot of the Net Income of Galderma Group N over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Galderma Group N financial statement analysis. It represents the amount of money remaining after all of Galderma Group N operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Galderma Group's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Galderma Group's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 231 M | 10 Years Trend |
|
Net Income |
| Timeline |
Galderma Net Income Regression Statistics
| Arithmetic Mean | (62,320,992) | |
| Geometric Mean | 143,809,479 | |
| Coefficient Of Variation | (249.13) | |
| Mean Deviation | 114,912,552 | |
| Median | (141,071,306) | |
| Standard Deviation | 155,258,992 | |
| Sample Variance | 24105.4T | |
| Range | 420M | |
| R-Value | 0.72 | |
| Mean Square Error | 12204.2T | |
| R-Squared | 0.53 | |
| Significance | 0.001 | |
| Slope | 22,285,060 | |
| Total Sum of Squares | 385685.7T |
Galderma Net Income History
Galderma Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Galderma Group is extremely important. It helps to project a fair market value of Galderma Stock properly, considering its historical fundamentals such as Net Income. Since Galderma Group's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Galderma Group's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Galderma Group's interrelated accounts and indicators.
Click cells to compare fundamentals
Galderma Group 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Galderma Group's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Galderma Group.
| 11/24/2025 |
| 02/22/2026 |
If you would invest 0.00 in Galderma Group on November 24, 2025 and sell it all today you would earn a total of 0.00 from holding Galderma Group N or generate 0.0% return on investment in Galderma Group over 90 days. Galderma Group is related to or competes with Alcon AG, Straumann Holding, Siegfried Holding, Lonza Group, PolyPeptide Group, Sonova H, and Ypsomed Holding. Galderma Group is entity of Switzerland. It is traded as Stock on SW exchange. More
Galderma Group Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Galderma Group's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Galderma Group N upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.48 | |||
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 6.79 | |||
| Value At Risk | (2.70) | |||
| Potential Upside | 2.15 |
Galderma Group Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Galderma Group's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Galderma Group's standard deviation. In reality, there are many statistical measures that can use Galderma Group historical prices to predict the future Galderma Group's volatility.| Risk Adjusted Performance | 0.0302 | |||
| Jensen Alpha | 0.0184 | |||
| Total Risk Alpha | (0.1) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.1303 |
Galderma Group February 22, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0302 | |||
| Market Risk Adjusted Performance | 0.1403 | |||
| Mean Deviation | 1.21 | |||
| Semi Deviation | 1.39 | |||
| Downside Deviation | 1.48 | |||
| Coefficient Of Variation | 3021.85 | |||
| Standard Deviation | 1.51 | |||
| Variance | 2.29 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | 0.0184 | |||
| Total Risk Alpha | (0.1) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.1303 | |||
| Maximum Drawdown | 6.79 | |||
| Value At Risk | (2.70) | |||
| Potential Upside | 2.15 | |||
| Downside Variance | 2.19 | |||
| Semi Variance | 1.94 | |||
| Expected Short fall | (1.34) | |||
| Skewness | 0.1301 | |||
| Kurtosis | (0.12) |
Galderma Group N Backtested Returns
At this stage we consider Galderma Stock to be very steady. Galderma Group N holds Efficiency (Sharpe) Ratio of 0.0397, which attests that the entity had a 0.0397 % return per unit of risk over the last 3 months. We have found thirty technical indicators for Galderma Group N, which you can use to evaluate the volatility of the firm. Please check out Galderma Group's Downside Deviation of 1.48, risk adjusted performance of 0.0302, and Market Risk Adjusted Performance of 0.1403 to validate if the risk estimate we provide is consistent with the expected return of 0.061%. Galderma Group has a performance score of 3 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.31, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Galderma Group's returns are expected to increase less than the market. However, during the bear market, the loss of holding Galderma Group is expected to be smaller as well. Galderma Group N right now retains a risk of 1.54%. Please check out Galderma Group coefficient of variation, jensen alpha, sortino ratio, as well as the relationship between the standard deviation and total risk alpha , to decide if Galderma Group will be following its current trending patterns.
Auto-correlation | -0.75 |
Almost perfect reverse predictability
Galderma Group N has almost perfect reverse predictability. Overlapping area represents the amount of predictability between Galderma Group time series from 24th of November 2025 to 8th of January 2026 and 8th of January 2026 to 22nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Galderma Group N price movement. The serial correlation of -0.75 indicates that around 75.0% of current Galderma Group price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.75 | |
| Spearman Rank Test | -0.3 | |
| Residual Average | 0.0 | |
| Price Variance | 37.87 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Galderma Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Galderma Group N reported net income of 231 M. This is 32.31% lower than that of the Healthcare sector and 159.98% lower than that of the Drug Manufacturers - Specialty & Generic industry. The net income for all Switzerland stocks is 59.54% higher than that of the company.
Galderma Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Galderma Group's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Galderma Group could also be used in its relative valuation, which is a method of valuing Galderma Group by comparing valuation metrics of similar companies.Galderma Group is currently under evaluation in net income category among its peers.
Galderma Fundamentals
| Return On Equity | 0.0492 | ||||
| Return On Asset | 0.0367 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 37.25 B | ||||
| Shares Outstanding | 234.82 M | ||||
| Shares Owned By Insiders | 35.77 % | ||||
| Shares Owned By Institutions | 41.63 % | ||||
| Price To Book | 5.95 X | ||||
| Price To Sales | 7.81 X | ||||
| Revenue | 4.44 B | ||||
| Gross Profit | 3.25 B | ||||
| EBITDA | 959 M | ||||
| Net Income | 231 M | ||||
| Cash And Equivalents | 175 M | ||||
| Total Debt | 2.76 B | ||||
| Book Value Per Share | 25.31 X | ||||
| Cash Flow From Operations | 429.77 M | ||||
| Earnings Per Share | 1.22 X | ||||
| Price To Earnings To Growth | 0.91 X | ||||
| Target Price | 166.2 | ||||
| Market Capitalization | 36.61 B | ||||
| Total Asset | 12.62 B | ||||
| Retained Earnings | 5.68 B | ||||
| Annual Yield | 0 % | ||||
| Net Asset | 12.62 B | ||||
| Last Dividend Paid | 0.17 |
About Galderma Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Galderma Group N's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Galderma Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Galderma Group N based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Galderma Stock Analysis
When running Galderma Group's price analysis, check to measure Galderma Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galderma Group is operating at the current time. Most of Galderma Group's value examination focuses on studying past and present price action to predict the probability of Galderma Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galderma Group's price. Additionally, you may evaluate how the addition of Galderma Group to your portfolios can decrease your overall portfolio volatility.